Kane’s research lies at the interface of biotechnology and nanotechnology. His group is designing nanoscale polyvalent therapeutics and working on the molecular engineering of biosurfaces and nanostructures. Kane was previously named by MIT’s Technology Review as one of the TR100 – the top 100 young innovators in the world.